Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus rating of "Hold" from the ten research firms that are currently covering the company, Marketbeat.com reports. One...